CDXC - ChromaDex Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.55
-0.03 (-0.84%)
As of 1:51PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.58
Open3.52
Bid3.54 x 1100
Ask3.56 x 1300
Day's Range3.50 - 3.59
52 Week Range3.19 - 7.24
Volume102,384
Avg. Volume227,190
Market Cap194.776M
Beta (3Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)-0.45
Earnings DateNov 7, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.25
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Science Behind TRU NIAGEN® to be Featured at the World Mitochondria Society Meeting

    ChromaDex Corp. (CDXC) announced today that it will present the science behind TRU NIAGEN® (nicotinamide riboside) at the 9th World Congress on Targeting Mitochondria 2018 in Berlin, Germany, from Oct. 23-25. Frank Jaksch, ChromaDex Co-Founder & Executive Chairman, will present “The Nicotinamide Riboside Journey, From Discovery To Clinical Efficacy” to the World Mitochondria Society to review the biochemical and physiological role of nicotinamide adenine dinucleotide (NAD) with an emphasis on the implications these processes have on healthy aging.

  • GlobeNewswire5 days ago

    Market Trends Toward New Normal in LSC Communications, Corindus Vascular Robotics, Sprouts Farmers Market, Luminex, ChromaDex, and CareDx — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire20 days ago

    TRU NIAGEN® PRO to be Featured at the North American Menopause Society (NAMS) Annual Meeting

    ChromaDex Corp. (CDXC) announced today that it will highlight its new TRU NIAGEN® PRO product at the NAMS Annual Meeting 2018 in San Diego, CA, beginning today through Oct. 6. NAD (nicotinamide adenine dinucleotide) is critical for mitochondria function, and healthy mitochondria are a vital part of healthy living as we age,” says gynecologist and NAMS member Alyssa Dweck, MS, MD, FACOG, Assistant Clinical Professor in the Department of Obstetrics, Gynecology and Reproductive Science at the Mount Sinai School of Medicine and a consultant at the Vincent Obstetrics and Gynecology Service at Massachusetts General Hospital. The sole active ingredient in Tru Niagen Pro is NIAGEN® nicotinamide riboside, a unique form of vitamin B3 clinically proven to safely increase one’s levels of NAD (nicotinamide adenine dinucleotide).

  • GlobeNewswire21 days ago

    ChromaDex Appoints Yan Chu as Managing Director, Asia Pacific

    ChromaDex Corp. (CDXC) announced today that it has appointed Yan Chu as Managing Director, Asia Pacific, effective today. Based in Singapore, Chu will lead the TRU NIAGEN® business for the region. Chu is joining ChromaDex from Comvita, an international health products company, where she served as Regional General Manager overseeing the Hong Kong, Japan, and Korea markets.

  • Simply Wall St.22 days ago

    Before You Buy ChromaDex Corporation’s (NASDAQ:CDXC), Consider This

    Anyone researching ChromaDex Corporation (NASDAQ:CDXC) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors Read More...

  • GlobeNewswire29 days ago

    TRU NIAGEN® Earns NSF International’s Certified for Sport® Certification

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced its TRU NIAGEN product recently earned certification from NSF International’s Certified for Sport® program and is available for purchase. The sole active ingredient in TRU NIAGEN is nicotinamide riboside, a unique form of vitamin B3 clinically proven to safely increase one’s levels of NAD (nicotinamide adenine dinucleotide) and enhance muscle recovery.

  • GlobeNewswirelast month

    TRU NIAGEN® PRO to be Featured at the Academy of Integrative Health & Medicine Annual Conference

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced it will exhibit at the AIHM Annual Conference 2018 in San Diego, CA. The sole active ingredient in Tru Niagen is nicotinamide riboside, a unique form of vitamin B3 clinically proven to safely increase one’s levels of NAD (nicotinamide adenine dinucleotide). At the Academy of Integrative and Health Medicine Annual Conference, taking place Sept. 22-26, integrative clinicians who embrace a patient-centered, team-based approach to healthcare will get their first look at the new Tru Niagen Pro product at booth #304.

  • GlobeNewswirelast month

    New TRU NIAGEN PRO Launched for Expansive Distribution by Healthcare Practitioners

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced the launch of TRU NIAGEN PRO (60ct, 300mg per capsule), a partnership with Natural Partners Fullscript, and a new online NAD education hub for healthcare practitioners. Tru Niagen Pro, which will be available exclusively for sale through healthcare practitioners, is the first of its kind, offering 60 capsules – each delivering 300 mg of Niagen® nicotinamide riboside (NR).

  • GlobeNewswirelast month

    ChromaDex and Dartmouth College File Patent Infringement Lawsuit Against Elysium Health

    IRVINE, Calif., Sept. 18, 2018-- ChromaDex Corp., an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN ® and consumer product ...

  • GlobeNewswirelast month

    ChromaDex Announces Strategic Partnership for Aging Research with Jiangxi Government in China

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced a strategic partnership for healthy aging research with the Jiangxi Provincial Government, People’s Republic of China. Wu Zhongqiong, Vice Governor of the People’s Government of Jiangxi Province, commenced the ceremony at the Jiangxi Qianhu State Guesthouse on Thurs., Sept. 13. Additional presentations followed from Madame Wang of Qifeng Food Technology, Dr. Katherine Lo of the Li Ka Shing Foundation, Robert Fried of ChromaDex, and Drs. Charles Brenner and Roger Kornberg of the ChromaDex Scientific Advisory Board.

  • GlobeNewswirelast month

    ChromaDex to Participate in “Conquering Aging” Briefing with Frost & Sullivan

    The live webinar, hosted by Frost & Sullivan, will take place on Tuesday, September 18, 2018, from 11:00 AM to 12:00 PM Eastern Time. Frank Jaksch, ChromaDex Co-Founder & Executive Chairman, will discuss nutraceuticals in the anti-aging space, the critical role of NAD (nicotinamide adenine dinucleotide), as well as the cutting-edge science behind TRU NIAGEN. TRU NIAGEN® is a branded dietary supplement brought to market by key nicotinamide riboside innovator and patent holder, ChromaDex.

  • GlobeNewswire2 months ago

    TRU NIAGEN® to be Highlighted at Vitafoods Asia 2018 in Singapore

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, today announced it will exhibit at Vitafoods Asia 2018. The sole active ingredient in TRU NIAGEN is nicotinamide riboside, a unique form of vitamin B3 clinically proven to safely increase one’s levels of NAD (nicotinamide adenine dinucleotide).

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CDXC earnings conference call or presentation 9-Aug-18 8:30pm GMT

    Q2 2018 Chromadex Corp Earnings Call

  • GlobeNewswire2 months ago

    ChromaDex to Present at the 7th Annual Liolios Gateway Conference on September 6, 2018

    IRVINE, Calif., Aug. 29, 2018-- ChromaDex Corp., an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN ® and consumer product TRU ...

  • GlobeNewswire2 months ago

    Recent Analysis Shows Global Brass and Copper, Ennis, ChromaDex, Caleres, Oil States International, and Chanticleer Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Aug. 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Global ...

  • Associated Press2 months ago

    ChromaDex: 2Q Earnings Snapshot

    The Irvine, California-based company said it had a loss of 15 cents per share. The natural products company posted revenue of $7.8 million in the period. In the final minutes of trading on Thursday, the ...

  • GlobeNewswire2 months ago

    ChromaDex Corporation Reports Second Quarter 2018 Financial Results   

    IRVINE, Calif., Aug. 09, 2018-- ChromaDex Corp., an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN ® and consumer product TRU ...

  • GlobeNewswire2 months ago

    ChromaDex to Launch TRU NIAGEN® in New Zealand with Retail Partner Matakana SuperFoods

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today the appointment of Matakana Superfoods (MSF) as the exclusive distributor of TRU NIAGEN in New Zealand. The sole active ingredient in TRU NIAGEN is nicotinamide riboside, a unique form of vitamin B3 clinically proven to safely increase one’s levels of NAD (nicotinamide adenine dinucleotide).

  • GlobeNewswire3 months ago

    ChromaDex and Watsons Expand TRU NIAGEN® Retail Partnership Through 2021

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today the expansion of its partnership with A.S. Watson Group until September 2021, as well as plans to launch TRU NIAGEN in Watsons Turkey in late 2018. “We are very fortunate to be working with Watsons and are quite happy with the success of TRU NIAGEN in Hong Kong.  We look forward to similar successes in other territories,” says Robert Fried, CEO of ChromaDex.

  • GlobeNewswire3 months ago

    ChromaDex Sets Second Quarter 2018 Financial Results on Thursday, August 9, 2018

    IRVINE, Calif., Aug. 02, 2018-- ChromaDex Corp., an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN ® and consumer product TRU ...

  • CNW Group4 months ago

    Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update

    VANCOUVER , June 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Board of Directors (the "Board") has elected Steve Rubin as Chairman of the Board, effective immediately. "I am honored to have the opportunity to work more closely with Fred and the rest of the Neovasc team as we advance the Company's development and commercial strategy for the Tiara and Reducer," stated Mr. Rubin.